Sunesis Reports Financial Results for the Second Quarter 2009
... and efficacy in AML and in platinum-resistant ovarian
cancer. These presentations can be found on the ... agent voreloxin in women with platinum-resistant ovarian
cancer were also presented at the ASCO 2009 ... Phase 2 single-agent trial in platinum-resistant ovarian
About Acute Myeloid Leukemia
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
... pregnancy rates in women undergoing controlled ovarian
stimulation (COS) with a standardized rFSH / ... weight categories. It showed that exposure and ovarian
response were similar after a single-dose of 100 ... development during the first week of ovarian
ENGAGE was a ...
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
... PSA levels in prostate cancer or CA-125 levels in ovarian
cancer were also observed. A reduction in PSA ... levels was observed in 3 of 5 patients (60%) with ovarian
"CTCs are emerging as an exciting ... and CA-125 levels in patients with prostate and ovarian
cancer, markers that strongly suggest single ...
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... of CA-125 and RECIST evaluation in recurrent ovarian
cancer (ROC): Results from a randomized phase III ... (CTC) in a study of relapsed/recurrent advanced ovarian
cancer: An exploratory analysis in the OVA-301 ... of life/patient-reported outcomes in relapsed ovarian
cancer: Results from a randomized phase III study ...
Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
... Commitment to the Development of Farletuzumab for ovarian
Agreement Highlights Lonza's Ability ... recently entered Phase III clinical trials for ovarian
cancer under a Special Protocol Assessment (SPA) ... bringing a new treatment option for patients with ovarian
Lonza is one of the ...
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
... patients with metastatic or resistant epithelial ovarian
cancer or advanced endometrial cancer."
... designation for ENMD-2076 for the treatment of ovarian
cancer. Several ovarian
cancer patients participated in the ENMD-2076 ...
ASCP Joins ACLU Lawsuit Opposing Gene Patents
... BRCA2 genes, which are associated with breast and ovarian
cancer. The lawsuit was filed against the U.S. ... BRCA2 genes, which are associated with breast and ovarian
cancer. The lawsuit (Case 1:09-cv-04515-RWS ... the person is at a higher risk of breast and/or ovarian
Women who fear they may be at an ...
BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management
... to First Develop Powerful Tools for Detecting ovarian
FRANKLIN LAKES, N.J. and ... The initial products will be directed to the ovarian
cancer biomarker, HE4, which is FDA-cleared for ... the progression or recurrence of epithelial ovarian
cancer. Fujirebio Diagnostics also grants BD, ...
NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer
... a multi-institutional collaborative project in ovarian
For the first phase of the project, ... mutations in preclinical models by profiling ovarian
cancer cells and ovarian
cancer stem cells. The consortium will also ...
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
... phase 2 monotherapy clinical study in recurrent ovarian
cancer. The study reported in the 2009 AACR ... phase 2 clinical study in patients with recurrent ovarian
cancer, and from in vitro data reported ... in Phase 2 clinical testing of patients with ovarian
cancer, and MuGard(TM) for the management of ...
Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
... regulatory clearance respecting the company's ovarian
tumor triage test ("OVA1") 510(k) pre-market ...
Vermillion has multiple ovarian
cancer diagnostic tests in development. The most ... women who were scheduled for surgery with an ovarian
mass. The data demonstrated that the OvaCalc ...
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
... of single-agent voreloxin in platinum-resistant ovarian
cancer patients at the 12th Biennial Meeting ... Phase 2 single-agent trial in platinum-resistant ovarian
About Acute Myeloid Leukemia
... need for new treatment options.
In the United ...
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
... AEZS-108 for a Phase 2 trial in advanced
and endometrial cancers.
- ... for AEZS-108
Phase 2 trial in advanced ovarian
and endometrial cancers.
- ... oncology compound, AEZS-108, in endometrial and ovarian
cancer with results expected by the end of this ...
Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
... Assay to Improve Diagnosis and Treatment of ovarian
FREMONT, Calif., Feb. 12 ... for the discovery of hepcidin as a biomarker for ovarian
cancer. The discovery could ultimately lead to ... with additional, valuable information to diagnose ovarian
"The notice of issuance of this ...
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
... 2 trials for acute myeloid leukemia (AML) and ovarian
cancer. The clinical update coincides with the ... the development of voreloxin in both AML and ovarian
cancer. We believe voreloxin has the potential ... enrollment of our Phase 2 platinum-resistant ovarian
cancer study and both of our ongoing AML studies ...
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
These results are important to ovarian
cancer treating physicians since
ovarian cancer ... clinical trial on 719 late stage epithelial ovarian
patients conducted by The European ... for response
to first-line treatment in advanced ovarian
Financial outlook 2008
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
... treat up to 82 women with LHRH-receptor positive ovarian
endometrial cancerous tumors. The primary ... compound,
AEZS-108 in both endometrial and ovarian
cancer. The data also strengthens
our belief that ... (up to 41
with a diagnosis of platinum-resistant ovarian
cancer and up to 41 with
disseminated endometrial ...
Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
... resistant or secondary
platinum resistant ovarian
cancer (definitions of platinum status ... well-balanced for patient
demographics and key ovarian
cancer disease characteristics. Telcyta ... About Platinum Refractory and Resistant ovarian
Platinum refractory or primary ...
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
... clinical trial on 719 late stage
cancer patients (named 55971). Results were ... for response to
first-line treatment in advanced ovarian
The clinical trial results ... is initiated. These results are important to ovarian
treating physicians ...
Ferring Celebrates Winner of 2008 My Little Miracle Essay Contest During National Infertility Awareness Week
... and BRAVELLE are not indicated in women with ovarian
uncontrolled thyroid and adrenal ... mild to
severe adverse reactions, including ovarian
Hyper Stimulation Syndrome
(OHSS), with or ... these medications. Like other products
stimulation, treatment with MENOPUR and/or ...
Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
... ("CO-eXpression ExtrapolatioN").
cancers are often diagnosed at the advanced stage ... believe physicians will be able to
quickly direct ovarian
cancer patients towards appropriate lines ... frequent cause of cancer death in women. In
cancer will be diagnosed in more than 20,000 ...
Abeome Forms First Class Scientific Advisory Board
... to collaborate on the development of
cancer project and to select and guide future ... and to participate in target validation on
cancer therapeutic project. Their active ... and clinical trials,
unparalleled knowledge of ovarian
cancer pathology, and years of ...
National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer'
... Host to Help Educate Women Nationwide About ovarian
LOS ANGELES, Sept. 6 /PRNewswire/ -- Today the National ovarian
Coalition (NOCC) and PureOlogy, its ... and PureOlogy's Walk to Break the Silence
Cancer" at Dockweiler Beach in Playa del Ray, CA. ...
33rd ESMO Congress in Stockholm, 12-16 September 2008
... from Flinders University in Australia.
Drug shows promise in ovarian
(Embargoed until Monday, 15 September ... CEST)
An investigational drug that combats ovarian
cancer by inhibiting the
formation of new blood ...
Rosetta Genomics Reports Second Quarter 2008 Financial Results
... These tests are focused on predicting response to ovarian
treatment, predicting risk of gastric ... - Predicting response to treatment of ovarian
cancer patients - Platinum-based cytotoxic ... gold standard of treatment for patients with ovarian
cancer. However, approximately 20-25% of patients ...
Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
speaker of the roundtable.
tumor triage test utilizes a panel of ... tumors are benign, studies show
that women with ovarian
cancer have improved median and overall ... by a gynecologic oncologist.
About Vermillion's ovarian
Cancer Diagnostic Program
In addition to ...
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
... Programs to Include Response Prediction to ovarian
Cancer Treatment, Predicting Risk of Gastric ... 1) Predicting response to treatment of ovarian
- Platinum-based cytotoxic ... biomarkers that may assist in
cancer patients expected to benefit from ...
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
... future clinical use of VASCLIR.
Cancer Diagnostic Program * Continued to ... the benefits of the Company's ovarian
cancer diagnostic test programs at the ... could help better identify women with early-stage ovarian
cancer and improve detection. * ...
Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
prescribing decisions in advanced ovarian
cancer. Clinical data and expert
opinion show ... the
current sales leader in ovarian
The new report entitled ovarian
Cancer (Advanced): Therapies Must
FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
... data on FAS31, FASgen's lead
compound for ovarian
cancer. FAS31 is an inhibitor of fatty acid ... inhibits fatty acid synthesis in SKOV3 human ovarian
in vitro (IC-50 = 6.09 +/- 0.4 ... successful mouse efficacy trials in human ovarian
cell lines, showing 80% reduction in ...
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
... programs for peripheral artery disease
cancer and thrombotic thrombocytopenic purpura ... of
2008, Vermillion has advanced its PAD and ovarian
programs, as well as ... exclusive rights to the biomarker panel.
Cancer Diagnostic Test Progress -- Received the ...
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
... treat up to 82 women with
LHRH-receptor positive ovarian
and endometrial cancerous tumors. The
primary ... (up to 41
with a diagnosis of platinum-resistant ovarian
cancer and up to 41 with
disseminated endometrial ... agents in inhibiting tumor growth.
and endometrial cancer
Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock
... Test Offers Most Accurate Measurement of Women's ovarian
ATLANTA, ... Dr. Perloe. "And while we know that
on average ovarian
reserve begins a more rapid decline after age 35, ... women
with the individual assessment of their own ovarian
reserve to help them
make more informed decisions ...
Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
... lead candidate, SNS-595, in platinum-resistant ovarian
will be featured in a poster session on ... in women with platinum refractory epithelial ovarian
* Poster Session A -Small Molecule ... 1b acute leukemia clinical trials
and a Phase 2 ovarian
cancer clinical trial. SNS-032, Sunesis' ...
ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens
... discovery company. These proprietary antigens specifically target breast, ovarian
and prostate cancers. IVT will combine the proprietary antigens with its ... DPX-0907 into Phase 1 clinical trials.
"Advanced-stage breast, ovarian
and prostate cancers remain devastating and challenging diseases that ...
New Report Just Published: World Endoscopy Systems Market Report
Fallopian & ovarian
Tubal Ligation II-32
Vagina Creation II-32
Laparoscopic Myomectomies II-32
Female Infertility II-33
Female Sterilization ...
Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
... exclusive national reference laboratory provider of the blood-based HE4 ovarian
Cancer Monitoring test, which is FDA-cleared as an aid in monitoring epithelial ovarian
cancer. The company is also developing a molecular blood test based on ...
Groundbreaking Research Begins for Pancreatic and Lung Cancers
... from the acclaimed work of Dr. McDonald and Benedict Beningo, MD, with ovarian
cancer patients, the current research is the first to focus on pancreatic ... to be the most fatal of common cancers. Pancreatic cancer is similar to ovarian
cancer in that it often goes undetected until the disease is too far ...
Cynvec to Present at the BIO National Venture Conference
... and highly significant survival rates in pre-clinical models of ovarian
and pancreatic cancer as both a single agent and in combination with ... diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in ovarian
cancer in the third quarter of 2009. The sindbis vector has also ...
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
... with advanced or metastatic solid tumours including pancreatic, lung and ovarian
cancers that are refractory (have not responded) to standard therapy or ...
Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian
cancer. For more information about Gemzar(R), please visit www.gemzar.com ...